PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that VetCove, Inc. has agreed to distribute PetVivo’s therapeutic product, SPRYNG™ with OsteoCushion™ Technology. VetCove owns and operates a licensed veterinarian ordering/purchasing platform used by over 13,000 veterinary hospitals to compare prices and purchase medications, food and veterinary supplies from multiple vendors at once.
“We are excited to announce that VetCove has approved for distribution our proprietary veterinary medical device, Spryng with OsteoCushion Technology, through its licensed veterinarian ordering/purchasing platform” said John Lai, Chief Executive Officer of PetVivo. “VetCove’s licensed veterinarian ordering platform introduces Spryng to more than 13,000 veterinary hospitals and provides veterinarians the opportunity to order and administer SPRYNG to dogs and horses suffering from osteoarthritis and other lameness afflictions.”
PetVivo’s innovative therapeutic product, Spryng™ with OsteoCushion™ Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural components, collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to replace and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic treatment.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact firstname.lastname@example.org or visit https://petvivo.com/
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is scheduled for expanded commercial sale in the fourth quarter of this year.
John Lai, CEO
PetVivo Holdings, Inc.
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.